Armand, Philippe <br/><br/>
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Nov 2013 
 - 4199-206 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2012.48.3685  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Chile<br/>Combined Modality Therapy<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Fatigue--etiology<br/>Female<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Immune Tolerance--drug effects<br/>India<br/>Israel<br/>Lymphocyte Count<br/>Lymphoma, Large B-Cell, Diffuse--blood<br/>Male<br/>Middle Aged<br/>Neutropenia--etiology<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Transplantation, Autologous<br/>Treatment Outcome<br/>United States<br/>Young Adult